Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.8M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$131M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Estepan Ian Michael | Aug 30, 2024 | Sell | 5,985 | $137.36 | $820,000 |
| Chambers Michael Andrew | Aug 16, 2024 | Buy | 18,284 | $134.06 | $2.5M |
| Chambers Michael Andrew | Aug 16, 2024 | Buy | 13,106 | $133.07 | $1.7M |
| Chambers Michael Andrew | Aug 16, 2024 | Buy | 5,648 | $134.66 | $760,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 17,581 | $162.65 | $2.9M |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 7,644 | $158.07 | $1.2M |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 4,168 | $161.82 | $670,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 3,840 | $163.53 | $630,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 2,549 | $164.52 | $420,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 2,200 | $159.14 | $350,000 |
| Arif Bilal | Jun 25, 2024 | Sell | 3,898 | $163.23 | $640,000 |
| Brown Ryan Edward | Jun 25, 2024 | Sell | 975 | $160.31 | $160,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 5,580 | $162.31 | $910,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 1,055 | $163.83 | $170,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 700 | $166.1 | $120,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 300 | $164.61 | $49,000 |
| Arif Bilal | Jun 24, 2024 | Sell | 224 | $167.13 | $37,000 |
| Murray Dallan | May 2, 2024 | Sell | 3,635 | $140 | $510,000 |
| Boor Kathryn Jean | Mar 11, 2024 | Sell | 761 | $122.93 | $94,000 |
| Wigzell Hans Lennart Rudolf | Mar 8, 2024 | Sell | 11,745 | $123.1 | $1.4M |
| Wigzell Hans Lennart Rudolf | Mar 8, 2024 | Sell | 3,155 | $123.85 | $390,000 |
| Wigzell Hans Lennart Rudolf | Mar 8, 2024 | Sell | 100 | $122.39 | $12,000 |
| Mayo Stephen | Mar 5, 2024 | Sell | 3,135 | $122.96 | $390,000 |
| Brown Ryan Edward | Mar 1, 2024 | Sell | 2,000 | $125.34 | $250,000 |
| Arif Bilal | Mar 1, 2024 | Sell | 1,543 | $128.58 | $200,000 |
| Estepan Ian Michael | Mar 1, 2024 | Sell | 1,200 | $128.3 | $150,000 |
| Arif Bilal | Mar 1, 2024 | Sell | 457 | $129.71 | $59,000 |
| Barry Richard | Nov 3, 2023 | Buy | 40,000 | $78.81 | $3.2M |
| Barry Richard | Nov 3, 2023 | Buy | 10,000 | $78.81 | $790,000 |
| INGRAM DOUGLAS S | Nov 3, 2023 | Buy | 11,060 | $79.7 | $880,000 |
| INGRAM DOUGLAS S | Nov 3, 2023 | Buy | 10,081 | $78.57 | $790,000 |
| INGRAM DOUGLAS S | Nov 3, 2023 | Buy | 3,884 | $80.33 | $310,000 |
| INGRAM DOUGLAS S | Nov 3, 2023 | Buy | 200 | $81.26 | $16,000 |
| Chambers Michael Andrew | Aug 14, 2023 | Buy | 5,947 | $109.19 | $650,000 |
| Chambers Michael Andrew | Aug 14, 2023 | Buy | 4,032 | $109.89 | $440,000 |
| Chambers Michael Andrew | Aug 11, 2023 | Buy | 23,686 | $108.05 | $2.6M |
| Chambers Michael Andrew | Aug 10, 2023 | Buy | 31,570 | $106.26 | $3.4M |
| Chambers Michael Andrew | Aug 10, 2023 | Buy | 2,206 | $104.67 | $230,000 |
| Chambers Michael Andrew | Aug 10, 2023 | Buy | 1,091 | $105.9 | $120,000 |
| Wigzell Hans Lennart Rudolf | Aug 4, 2023 | Sell | 15,000 | $106.72 | $1.6M |
| Mayo Stephen | Nov 17, 2022 | Sell | 858 | $109.92 | $94,000 |
What's the latest insider transaction for Sarepta Therapeutics?
The most recent insider transaction for Sarepta Therapeutics was conducted by Estepan Ian Michael, who sold 5,985 shares on August 30, 2024 at a price of $137.36 per share.
Which insider bought the most SRPT stock over the last two years?
Chambers Michael Andrew has bought the most SRPT stock in the last 2 years, with a total value of $12M.
Which insider has sold the most SRPT stock over the last two years?
Brown Ryan Edward has sold the most SRPT stock in the last 2 years, with a total value of $6.5M.
What is the total value of insider transactions for Sarepta Therapeutics (SRPT) in the last 2 years?
According to our estimates, the total value of insider transactions for Sarepta Therapeutics in the last 2 years is positive, amounting to $4M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Sarepta Therapeutics' market confidence?
Over the last 2 years, insider transactions for Sarepta Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
